Finland’s National Institute for Health and Welfare joins SNOMED International as the organization’s 36th Member.
London, United Kingdom, Dec. 19, 2018 (GLOBE NEWSWIRE) -- SNOMED International and the Finnish National Institute for Health and Welfare (THL) are pleased to announce that Finland has joined the organization as its thirty-sixth Member.
Finland, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority and has quickly become a pioneer in digital health. Its largest national digital healthcare project, the Kanta Service, i.e. the National Archive of Health Information, is one of the most comprehensive systems of its kind globally, covering already the entire Finnish public healthcare sector as well as most of the private sector. The development of Kanta Service began around 2005, and the first laws concerning the digital service were enacted in 2007.
A prerequisite to this being the development of information systems and standards and particularly their usability. The Kanta Service is a collaborative undertaking among the Social Insurance Institution of Finland (Kela), the National Institute for Health and Welfare (THL), the Ministry of Social Affairs and Health, and various social and healthcare organizations.
As the newest SNOMED International Member, Finland will leverage SNOMED CT’s
structured clinical vocabulary to structure its Kanta Service and realize improvements in how clinical data is recorded, analyzed and reported on for the benefit of patient care. Finland’s commitment to SNOMED CT sets a foundation for clinical data to be exchanged accurately and consistently across Finnish health and social care settings, further extending the reach of structured clinical terminology throughout the European region.
To make best use of SNOMED CT with available resources, Finland has chosen not to translate the whole terminology. Instead, the aim is to focus on two national reference sets that meet local needs in areas where there is international experience and models showing implementation success. The first target is an obvious one: standardizing the terminology and codes for anatomic pathology in the clinical laboratories. Finnish pathology laboratories have used SNOMED 2 since 1980’s. But lack of coordination eventually resulted in several dialects and variance between hospitals. Now the ongoing project aims at national reference set to help the biobanks, regional and national quality registers and structured reporting on individual patient basis.
The other chosen application for SNOMED CT is patient problem list. Finland decided to use CORE Problem List as foundation for the local effort. CORE Problem List originated from a respectable group of medical institutions in the U.S. and is maintained by the National Medical Library thus making the acceptance of the reference set by clinicians so much easier. The ongoing project translates terminology into Finnish and when finished will cover terms for both professionals and patients. Our aim is to have these first two applications ready at the first half of 2020. SNOMED CT National Release Center will gradually take off during 2019 and 2020 to meet the needs for services and support during SNOMED CT local implementations. SNOMED CT NRC will be essential part of THL Code Service.
SNOMED CT is the world’s most comprehensive health terminology. Founded in 2007 by nine charter nations, SNOMED International is a not-for-profit, member-owned and driven international organization. CEO, Don Sweete, is excited to add Finland to SNOMED International’s European Member base. “Finland’s leading-edge digital expertise stems from years as leaders of the information technology and communications industry.” Since then, the strong Finnish ICT experience has permeated nearly every industrial sector including health. Digital health technology is certainly one of the most compelling and promising of these fields with the Kanta Service, and Finland’s commitment to adopting SNOMED CT’s clinical terminology to support care delivery, data analysis and research is encouraging.”
Finland is the twenty-third country in the Europe, Middle East and African region (EMEA) to join SNOMED International, strengthening the position of the area for increased interoperability amongst its regional and international counterparts as was echoed in the 2017 ASSESS CT report.
To learn more about SNOMED International and SNOMED CT, visit www.snomed.org.
To learn more about Finnish healthcare visit https://thl.fi/en/web/information-management-in-social-welfare-and-health-care. For more information on Kanta services visit http://www.kanta.fi/en and http://www.finlandhealth.fi/home.
About SNOMED International:
SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world's most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organisation (IHTSDO.)
YouTube: SNOMED International
About National Institute for Health and Welfare (THL):
The National Institute for Health and Welfare (THL) is responsible for the operative guidance of the information management in social welfare and health care. As a statistical authority THL is responsible for the maintenance and development work of the statistical and register repositories and national classifications. The Operational Management Unit is responsible for the operational management of health and welfare information manages the national development of health and welfare information gives hospital districts, health centres, private health service providers, and pharmacies guidance in carrying out information-system reforms so that the introduction of services is managed within the time frames defined by law. We are an independent, expert agency working under the Ministry of Social Affairs and Health.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Test Release - 3-21-2019 - 119240921.3.2019 20:29:00 CET | Pressemelding
Test Sub Headline - 1951992 Chicago, March 21, 2019 (GLOBE NEWSWIRE) -- Test Release™. Attachment sample
Blackhawks, Flyers, Sabres and Lightning Headline the 2019 NHL Global Series21.3.2019 15:34:00 CET | Pressemelding
Chicago Blackhawks and Philadelphia Flyers to Open Regular Season in Prague, Czech Republic on Oct. 4 Buffalo Sabres and Tampa Bay Lightning to Face Off in a Pair of Games in Stockholm, Sweden on Nov. 8 and Nov. 9 2019 NHL Global Series Challenge to feature Blackhawks vs. Eisbären Berlin on Sept. 29 in Berlin, Germany and Flyers vs. Lausanne HC on Sept. 30 in Lausanne, Switzerland Tickets to Games in Berlin, Prague and Stockholm Available for Purchase on Wednesday, March 27; Tickets to Game in Lausanne Available for Purchase on Wednesday, April 10 NEW YORK/TORONTO, March 21, 2019 (GLOBE NEWSWIRE) -- The National Hockey League (NHL) and the National Hockey League Players’ Association (NHLPA), in conjunction with Live Nation Sweden, today announced that the Buffalo Sabres, Chicago Blackhawks, Philadelphia Flyers and Tampa Bay Lightning will participate in the 2019 NHL Global Series. The Chicago Blackhawks and Philadelphia Flyers will play their 2019-20 season-opening game against each ot
Farmako: World's Largest Import Contract for Pharmaceutical Cannabis21.3.2019 15:10:00 CET | Pressemelding
German Farmako secures 50 tonnes of flowers and oils from Polish company Pharmacann Polska FRANKFURT, March 21, 2019 (GLOBE NEWSWIRE) -- Farmako will import 50 tonnes of pharmaceutical cannabis from Pharmacann Polska into the European market over the next four years. This provides the basis for a reliable supply of pharmaceutical cannabis for millions of patients in the European healthcare system. The company expects a total revenue of several hundred million Euros from the agreed exclusive partnership. Founded in September 2018, Farmako now has grown to 40 employees and is distributing high-quality pharmaceutical cannabis to German pharmacies since March 2019. This is the biggest Cannabis contract to date, and the first big contract without participation of a Canadian LP. Farmako has signed an exclusive and binding agreement to import and distribute 50 tons of pharmaceutical cannabis over four years. Farmako and Pharmacann Polska enter strategic partnership to develop custom tailored
NexOptic Appoints Rich Geruson, Former Lexmark CEO, to Board of Directors21.3.2019 14:00:00 CET | Pressemelding
VANCOUVER, British Columbia, March 21, 2019 (GLOBE NEWSWIRE) -- NexOptic Technology Corp. ("NexOptic" or the "Company") (TSX VENTURE: NXO) (OTCQX: NXOPF) (FRANKFURT: E3O1) is pleased to announce that Richard J. (Rich) Geruson has joined its Board of Directors, effective immediately. Mr. Geruson’s experience spans CEO roles at Lexmark International, Phoenix Technologies and VoiceSignal Technologies, and Senior Vice President and executive positions at Nokia, IBM, Toshiba, and McKinsey & Co. As CEO of Lexmark International, a multibillion-dollar imaging technology and solutions company with 10,000 employees, he grew printer sales faster than at any time in the preceding 10 years while simultaneously executing extensive process reengineering, transforming the business from negative EBITDA and high debt to positive multi-hundred-million-dollar EBITDA and a healthy debt profile. While CEO of Phoenix Technologies, he achieved consistently high profit year-over-year for six years straight in
Standard Lithium Announces Closing of $11.4 Million Bought Deal Including Partial Exercise of Over-Allotment Option21.3.2019 14:00:00 CET | Pressemelding
VANCOUVER, British Columbia, March 21, 2019 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L) is pleased to announce that it has closed its previously announced bought deal offering (the “Offering”), including the partial exercise of the over-allotment option. A total of 11,390,500 units (the “Units”) of the Company were issued at a price of $1.00 per Unit for gross proceeds of $11,390,500. Each Unit is comprised of one common share and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a “Warrant”). Each Warrant is exercisable to acquire one common share of the Company at an exercise price of $1.30 per share, subject to adjustment in certain events, until March 21, 2022. The Units were offered and sold by way of a short form prospectus filed in each of the provinces of Canada, excluding Quebec, and offered and sold elsewhere outside of Canada on a private placement
Crown Bioscience to Present Latest Advancements in Preclinical and Translational Platforms at AACR Annual Meeting 201921.3.2019 13:30:00 CET | Pressemelding
15 posters present data from novel models to evaluate new cancer therapeutics SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the presentation of 15 scientific posters at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, GA from March 29 to April 3. The scientific posters highlight the latest advancements in CrownBio’s integrated oncology and immuno-oncology platforms built on the world’s largest and unique experimental model libraries, including patient-derived xenografts (PDXs), innovative humanized mouse models, GEMM, syngeneic mouse tumor homografts, PDX derived organoids (PDXO), and uniquely developed analytic methods. Featured posters will present data from novel models that enable detailed evaluation of new cancer therapeutics, including targeted cancer i